跳至主要内容
临床试验/NCT02852902
NCT02852902已完成不适用

Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to ESBL- or Carbapenemase-producing Enterobacterales in Solid Organ Transplantation: an Observational Multinational Study.

Spanish Network for Research in Infectious Diseases3 个研究点 分布在 1 个国家目标入组 820 人开始时间: 2016年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
820
试验地点
3
主要终点
Cure rate

研究概览

简要总结

Main objective: to observationally assess the efficacy and safety of different antimicrobials in BSI due to ESBL or carbapenemase-producing Enterobacterales in SOT.

Secondary objectives:

  1. To evaluate the efficacy and safety of different antibiotics used for the treatment of infections caused by ESBL- and carbapenemase-producing Enterobacterales in the SOT population.
  2. To compare the efficacy of different antimicrobials between SOT and non-SOT patients (using matched controls from the "non-transplant" INCREMENT cohort).
  3. To create a microbiological collection of ESBL- and carbapenemase-producing Enterobacterales isolated from the SOT population.
  4. To provide data on specific MICs for each antimicrobial evaluated.
  5. To provide data on the prevalence of specific mechanisms of resistance and their clinical impact in the particular setting of SOT.
  6. To organise an international consortium capable of developing high quality prospective cohort studies and randomised clinical trials in the area of MDR and XDR Enterobacterales in SOT.

详细描述

METHODS

Study design: multicentre, international retrospective cohort study.

Sites: multiple expert investigators from different countries will be invited. Criteria for participation will include accessibility to a database with the required data or ability to retrospectively collect the data in a timely manner.

Procedure Centers will receive by email a personal key for access to an electronic Case Report File (CRF), on the official INCREMENT-SOT website at http://www.increment-sotproject.org/

The participant centres will be requested to include:

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Solid Organ Transplant patients, including multivisceral transplantation and transplant in HIV-infected recipients.
  • Episodes of clinically significant monomicrobial BSI due to cephalosporin-resistant Enterobacterales (CRE), specifically ESBL or carbapenemase-producing Enterobacterales, including community and nosocomial ones. Characterization of the resistance mechanisms should be based on the following criteria:
  • For cephalosporin resistance: a susceptibility phenotype based on a microdilution antibiogram.
  • For ESBL-producers: one phenotypic confirmation test according to current endpoints (i.e. CLSI, EUCAST) or PCR-based characterization.
  • For carbapenemase-producers: molecular detection of the carbapenemase gene or if the isolate showed an identical phenotype to previously characterized carbapenemase-producers detected at the same site.
  • Subsequent episodes in a patient caused by the same microorganism may be included if the interval between them is >3 months.

排除标准

  • Polymicrobial or non-clinically significant episodes. Episodes in which a potential contaminant (e.g., coagulase-negative staphylococci) is isolated only in one set of blood cultures and there is not a typical source of infection for that kind of organism (e.g. catheter-related) that can be included.
  • Unavailability of key data (such cases should be counted to analyse a potential selection bias).
  • Episodes occurring before January 2004.

结局指标

主要结局

Cure rate

时间窗: 14 days

Cure: resolution of all signs and symptoms related to the infection, and antibiotic therapy is no longer necessary

次要结局

  • Clinical Improvement at 72 hours(72 hours)
  • Clinical cure at 28 days(28 days)
  • Mortality at 72 hours(72 hours)
  • Mortality at 7 days(3 days)
  • Mortality at 14 days(14 days)
  • Mortality at 30 days(30 days)

研究者

发起方
Spanish Network for Research in Infectious Diseases
申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验